Collegium Pharmaceutical Inc (COLL) Stock Forecast
Show ratings and price targets of :
Alert
Its only available to paid users.
USD 41.67
(+39.07%)
Based on the Collegium Pharmaceutical Inc stock forecast from 4 analysts, the average analyst target price for Collegium Pharmaceutical Inc is USD 41.67 over the next 12 months. Collegium Pharmaceutical Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Collegium Pharmaceutical Inc is Slightly Bullish , which is based on 8 positive signals and 4 negative signals. At the last closing, Collegium Pharmaceutical Inc’s stock price was USD 29.96. Collegium Pharmaceutical Inc’s stock price has changed by +1.28% over the past week, -16.52% over the past month and +15.32% over the last year.
No recent analyst target price found for Collegium Pharmaceutical Inc
No recent average analyst rating found for Collegium Pharmaceutical Inc
Company Overview Collegium Pharmaceutical Inc
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts. Read Less
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of ...Read More
Frequently Asked Questions About Collegium Pharmaceutical Inc (COLL) Stock
Based on ratings from 4 analysts Collegium Pharmaceutical Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 4 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on COLL's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for COLL is USD 41.67 over the next 12 months. The maximum analyst target price is USD 50 while the minimum anlayst target price is USD 37.
COLL stock's Price/Earning ratio is 12.82.
Our analysis grades COLL stock's Price / Earning ratio at D. This means that COLL stock's Price/Earning ratio is above 37% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this COLL may be fairly valued for its sector
The last closing price of COLL's stock was USD 29.96.
The most recent market capitalization for COLL is USD 0.97B.
Based on targets from 4 analysts, the average taret price for COLL is projected at USD 41.67 over the next 12 months.
This means that COLL's stock price may go up by +39.07% over the next 12 months.
We can't find any ETFs which contains Collegium Pharmaceutical Inc's stock.
As per our most recent records Collegium Pharmaceutical Inc has 197 Employees.
Collegium Pharmaceutical Inc's registered address is 100 Technology Center Drive, Stoughton, MA, United States, 02072.
You can get more information about it from Collegium Pharmaceutical Inc's website at https://www.collegiumpharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Collegium Pharmaceutical Inc (COLL) Stock
Based on ratings from 4 analysts Collegium Pharmaceutical Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 4 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on COLL's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for COLL is USD 41.67 over the next 12 months. The maximum analyst target price is USD 50 while the minimum anlayst target price is USD 37.
COLL stock's Price/Earning ratio is 12.82.
Our analysis grades COLL stock's Price / Earning ratio at D. This means that COLL stock's Price/Earning ratio is above 37% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this COLL may be fairly valued for its sector
The last closing price of COLL's stock was USD 29.96.
The most recent market capitalization for COLL is USD 0.97B.
Based on targets from 4 analysts, the average taret price for COLL is projected at USD 41.67 over the next 12 months.
This means that COLL's stock price may go up by +39.07% over the next 12 months.
We can't find any ETFs which contains Collegium Pharmaceutical Inc's stock.
As per our most recent records Collegium Pharmaceutical Inc has 197 Employees.
Collegium Pharmaceutical Inc's registered address is 100 Technology Center Drive, Stoughton, MA, United States, 02072.
You can get more information about it from Collegium Pharmaceutical Inc's website at https://www.collegiumpharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for COLL !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
